IP Library Granted Patent US 7,226,922
Granted Patent B2
US 7,226,922 · App. 10/680,855 · Granted Jun 5, 2007

Imidazo[1,2-b]pyridazine analogues as anxiolytics and cognition enhancers

Assignee: Merck Sharp & Dohme Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,226,922
App. No.
10/680,855
Granted
Jun 5, 2007
Kind
B2
Abstract

The present invention provides a compound of formula I: wherein X 1 represents hydrogen, halogen, C 1-6 alkyl, trifluoromethyl or C 1-6 alkoxy; X 2 represents hydrogen or halogen; Y represents a chemical bond, an oxygen atom, or a —NH— linkage; Z represents an optionally substituted aryl or heteroaryl group; R 1 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, —OR a , —SR a , —SOR a , —SO 2 R a , —SO 2 NR a R b , —NR a R b , —NR a COR b , —NR a CO 2 R b , —COR a , —CO 2 R a , —CONR a R b or —CR a ═NOR b ; and R a and R b independently represent hydrogen, hydrocarbon or a heterocyclic group; pharmaceutical compositions comprising this compound and methods of treating and/or preventing anxiety and convulsions using it.

Claims (17)

1. A compound of formula IIB, or a pharmaceutically acceptable salt thereof:

wherein:

R 6 represents hydrogen or fluoro;

R 11 represents trifluoromethyl or methyl;

X 11 represents hydrogen or fluoro; and

X 12 represents hydrogen or fluoro.

2. The compound of claim 1 wherein R 6 is hydrogen.

3. The compound of claim 1 wherein R 6 is fluoro which is attached to the phenyl ring at the 4-, 5- or 6-position (relative to the cyano group at the 2-position of the phenyl ring).

4. The compound of claim 1 wherein R 11 is trifluoromethyl.

5. The compound of claim 1 wherein R 11 is methyl.

6. The compound of claim 1 wherein X 11 is fluoro.

7. The compound of claim 1 wherein X 12 is hydrogen.

8. The compound of claim 1 wherein X 12 is fluoro.

9. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

10. A compound which is selected from:

3′-(7-Methylimidazo[1,2-b]pyridazin-3-yl)biphenyl-2-carbonitrile, or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising the compound of claim 10 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2007
From: HALLETT, DAVID JAMES
To: MERCK SHARP & DOHME LTD.
Reel/Frame 019201/0417 →
Priority Claims (1)
GB 0223349.2 · Oct 8, 2002 · national
Continuity (1)
Related Publication 20040067948A1 · Apr 8, 2004